insights_auto
Why is BH3 down 4.54%?
Dive Deeperchevron_right
BH3:ETR
PTC Therapeutics, Inc.
€52.56
arrow_downward
-4.54%(-2.50) 1D
Nov 20, 5:35:38 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BH3...
Open
€54.72
High
€54.72
Low
€52.52
Mkt. cap
4.71B
Avg. vol.
46.00
Volume
0.00
52-wk high
€78.18
52-wk low
€52.52
No. of employees
991
Open
€54.72
High
€54.72
Low
€52.52
Mkt. cap
4.71B
Avg. vol.
46.00
Volume
0.00
52-wk high
€78.18
52-wk low
€52.52
No. of employees
991
News stories
From web sources and news partners
The Motley Fool
·
1 hour ago
The S&P 500 Is 14 for 14 After Midterm Elections. Here’s How I’d Invest Now.
TradingKey
·
6 hours ago
S&P 500 Falls Below 200-Day Moving Average: Buy-the-Dip Opportunity or Bear Market Warning?
Beinsure
·
16 hours ago
Vanguard S&P 500 ETF: How investing in VOO could build a $1 mn portfolio
StoneX
·
2 days ago
S&P 500, Nasdaq 100 Drive into Correction Territory
Profile
PTC Therapeutics, Inc. is an U.S.-based pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapies that alter gene expression via post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees991
FoundedJan 1, 1998
HeadquartersWarren, New Jersey, United States
SectorHealth Care
IndustryBiotechnology
Websiteptcbio.com